Antitumor effect of 2,6-di(2,3-epoxypropoxy)xanthone on tumor cell lines

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 1107-1114

  Liu, Hsiao Sheng ^a,c   Lin, Chun Nan ^b   Won, Shen Jeu ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Antitumor; Colony formation; Ha ras; Transformation; Xanthone

Indexed keywords

2,6 DI(2,3 DIEPOXYPROPOXY)XANTHONE; MITOMYCIN C; RNA; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG MECHANISM; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SYNTHESIS;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; DNA; EPOXY COMPOUNDS; GENES, RAS; HUMANS; MICE; MITOMYCIN; PROTEIN BIOSYNTHESIS; RNA; TUMOR CELLS, CULTURED; XANTHENES; XANTHONES;

EID: 0030974570     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Habib AM, Ho DK, Masuda S, Mccloud T, Reddy KS, Aboushoer M, Mckenzie A, Byrm SR, Chang CJ and Cassady JM: Structure and stereochemistry of psorospermin and related cytotoxic dihydrofurano xanthones from Psorospernum febrifugum. J Org Chem 52: 412-418, 1987.
2. Fujimoto Y, Zhang XX, Kirisawa M, Uzawa J and Sumatra M:New flavones from Artocarpus communis Forst. Chem Pharm Bull 38: 1787-1789, 1990.
3. Lin CN and Shieh, WL: Prenylflavonoids and pyranodihydrobenoxanthone from Atrocarpus communis. Phytochemistry 30: 1669-1671, 1991.
4. Shieh WL and Lin CN: Quinonoid pyranobenzoxanthone and pyranodihydrobenzoxanthone from Artocarpus communis. Phytochemistry 31: 364-367, 1992.
5. Lin CN, Shieh WL, Liou SS, Cheng TH and Won SJ: γ-pyrone compounds as potential anti-cancer drugs. J Pharm Pharmacol 45: 791-794, 1993.
6. Feinberg AP and Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92, 1983.
7. Shiraswa S. Furase M, Yokoyama N and Sazazuki T: Altered growth of human colon cancer dell lines disrupted at activated Ki-ras. Science 260: 85-88, 1993.
8. Barbacid M: ras genes. Annu Rev Biochem 56: 779-827, 1987.
9. Bos JL: ras oncogencs in human cancer: a review. Cancer Res 49: 4082-4689, 1989.
10. Capon DJ, Chen EY, Levinson AD, Seeburg PH and Goeddel DV: Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 302: 33-37, 1983.
11. Downward J: Regulatory Mechanisms for ras proteins. BioEssays 14: 177-184.
12. Prendergast GC and Gibbs JK: Ras regulatory interactions: novel targets for anticancer intervation? BioEssays 16: 187-191, 1994.
13. Gibbs JB: Ras C-terminal processing enzymes-new drug targets? Cell 65: 1-4, 1991.
14. Liu HS, Scrable H, Villaret DB, Lieberman MA and Stambrook PJ: Control of Haras-mediated mammalian cell transformation by Escherichia coli regulatory elements. Cancer Res 52: 983-989, 1992.
15. Der C, Krontiris T and Copper G: Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma virus. Proc Natl Acad Sci USA 79: 3637-3640, 1982.
16. Parada L, Tabin C, Shih C and Weinberg R: Human EJ bladder carcinoma oncogene is a homologue of Harvey sarcoma virus ras gene. Nature 297: 474-478, 1982.
17. Denko NC, Giaccin AJ, Stringer JR and Stambrook PJ: The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci USA 91: 5124-5128, 1994.
18. Wani MA, Xu X and Stambrook PJ: Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells. Cancer Res 54: 2504-2508, 1994.
19. Tseng A, Lee WMF, Kirsten E, Hakam A. Mclick J, Buki K and Kun E: Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly(ADP ribose) polymerase. Proc Natl Acad Sci USA 84: 1107-1111, 1987.
20. Saito H, Morizane T, Watanabe T, Kagawa T, Miyagnchi S, Kumagai N, Tsuchimoto K and Tsuchiyn M: Proto-oncogene expression in three hepatoma cell lines HCC-M, HCC-T and PLC/PRF/5. Keio J Medicine 40: 139-145, 1991.
21. Ito M: Microassay for Studying anticellular effects of human interferons. J Interferon Res 4: 603-608, 1984.
22. Bhuyan BK, Newell KA, Crampton SL and Von HOFF: DD CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. Cancer Res 42: 3532-3537, 1982.
23. Maniatis T, Fritsch EF and Samhrook J (eds): Molecular cloning: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
24. Seliger B and Pettersson H: 7-Hydroxycoumarin inhibits oncogene induced transformation of murine fibroblasts. J Cancer Res and Clin Oncol 120Suppl: s23-s27, 1994.
25. Kohl NE, Mosser SD, Desolms SJ, Giuljiani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A and Gibbs JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1936, 1993.
26. 2b Kohl NE, Wilson FR, Mosser SD, Giuliani E, Desolms, SJ, Conner, MW, Anthony, NJ, Holtz, WJ, Gomez RP, Lee TJ, Smith RL, Graham SL, Hartman GD, Gibbs, JB and Oliff A: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145, 1994.
27. James GI, Goldstein JI, Brown MS, Rawson TE, Somers TC, Mcdowell RS, Crowley CW, Lucas BK, Levinson AD and Marsters JC: Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 260: 1937-1942, 1993.
28. Kadam S and Mcalpine, JB: Dorrigocins: novel antifungal antibiotics that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. J Antibiot 47: 875-880, 1994.
29. Mayfield C and Miller D: Effect of abasic linker substitution on triplex formation Spl binding, and specificity in an oligonucleotide targeted to the human Ha-ras promoter. Nucleic Acid Res 22: 1909-1916, 1994.
30. Coulson CJ (ed): Molecular mechanisms of drug action. 294pp, Taylor and Francis, PA, 1994.
31. Mann J: Nature's anticancer agents. Nature 361: 21-22, 1993.